LCAST vs GeneRx

The Lurie Children’s Child Injury Plausibility Assessment Support Tool (LCAST) is an app based on a validated Bruising Clinical Decision Rule (BCDR) called the TEN-4-FACESp. Use of this tool has the potential to improve recognition of abuse in young children with bruising. This app functions only as a screening tool and cannot be used to diagnose abuse. The app applies to children less than 4.0 years of age with bruising. If the child is older than 4.0 and/or bruising is not present, this tool cannot be used. In those circumstances, alternative methods of screening for abuse are needed. WHY FOCUS ON BRUISING? Bruising is the most common injury resulting from physical abuse and is the most overlooked or misdiagnosed antecedent injury prior to an abuse-related fatality or near-fatality in a young child. Bruising occurs from both accidental and abusive trauma, but differences identified by the TEN-4-FACESp bruising clinical decision rule may allow improved and earlier recognition of the abused child. ABOUT THE APP: The app is intended for clinical use by licensed healthcare professionals and providers. The app can inform decision-making and be used as an educational tool for learning about bruising characteristics that commonly result from abusive and accidental injury. The core feature of the app is an interactive 3D body model that allows the user to utilize visual cues of the human body to input clinical observations. The result is the opportunity to compare a child’s bruise findings to the published evidence resulting from a NIH-funded multi-center study. The data that drive the app are based on 2,161 patients of which 410 (19%) were classified by a multi-disciplinary panel of medical experts as abuse and 1,713 (79%) as accident. The TEN-4-FACESp bruising clinical decision rule resulted from analysis of 35 body regions and is 96% specific and 87% sensitive for distinguishing bruising from abuse versus accident. The TEN-4-FACESp has three components based on: 1) specific body regions with bruising, 2) patterned bruising, and 3) bruising anywhere on non-mobile infants. An affirmative finding for any one of the three TEN-4-FACESp components without a clear and reasonable explanation indicates a potential risk for abuse. The child may warrant further evaluation and consultation with an expert in child abuse should be considered. In addition to using the data in this app, the user should always check with a doctor before making any medical decisions.

GeneRX is an educational iOS application designed to demonstrate pharmacogenetic principles and help users understand how genetic variations can influence medication response. The app provides insights about gene-drug interactions in an accessible, user-friendly format, powered by data and guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC). IMPORTANT DISCLAIMER This application is for EDUCATIONAL PURPOSES ONLY. Users should NOT use this app to make medical decisions. All medication and dosing decisions must be made in consultation with qualified healthcare providers. Data Attribution This app is powered by: - CPIC (Clinical Pharmacogenetics Implementation Consortium) - cpicpgx.org - Comprehensive pharmacogenetic guidelines and recommendations - Real-time API for current clinical recommendations - Evidence-based gene-drug interaction data - Peer-reviewed dosing guidelines We gratefully acknowledge CPIC for making their pharmacogenetic data freely available for educational and research purposes. CPIC is a shared project between PharmGKB and the Pharmacogenomics Research Network. Key Features Manual Genetic Variant Input - Select from 33+ CPIC-annotated pharmacogenetic genes - Choose specific diplotype variants based on CPIC data - Build a personal variant profile for educational exploration Comprehensive Drug Database - Access to 3,803+ medications from CPIC/PharmGKB database - 87 drugs with specific CPIC dosing guidelines - Search functionality for finding specific medications - Clear indicators for drugs with CPIC guidelines Risk Level Visualization - Color-coded recommendations based on CPIC guidelines: - Green: Standard dosing appropriate - Orange: Dose adjustment may be needed - Red: Consider alternative medication - Visual learning about CPIC medication safety classifications Real-Time CPIC API Integration - Fetches current recommendations directly from CPIC API - Displays CPIC evidence levels (Strong, Moderate, Optional) - Direct links to official CPIC guidelines - Most up-to-date CPIC recommendations Educational Use Cases - Students: Learn pharmacogenetic concepts using real CPIC data - Healthcare Trainees: Understand CPIC guidelines and clinical implementation - Patients: Educational preparation for pharmacogenetic testing discussions - Educators: Demonstrate CPIC guidelines in classroom settings - General Public: Increase awareness of precision medicine Privacy and Safety - No data persistence between sessions - No user accounts or registration required - Anonymous usage only - No tracking or analytics - Session-only storage - Educational focus - not for clinical use Sample Gene-Drug Interactions All interactions based on official CPIC guidelines: - TPMT + Thiopurines (azathioprine, mercaptopurine) - CYP2C19 + Clopidogrel, SSRIs, PPIs - CYP2D6 + Codeine, Tramadol, Antidepressants - SLCO1B1 + Statins (simvastatin, atorvastatin) - CYP2C9/VKORC1 + Warfarin - DPYD + Fluoropyrimidines (5-FU, capecitabine) - HLA-B + Carbamazepine, Abacavir - And all other published CPIC gene-drug pairs CPIC Resources: - Official Website: cpicpgx.org - Guidelines: cpicpgx.org/guidelines - API Documentation: api.cpicpgx.org Important Notes - Educational tool demonstrating CPIC pharmacogenetic guidelines - Not a substitute for professional medical advice - Interpretation of CPIC guidelines requires qualified healthcare providers - Always consult medical professionals for medication decisions - For educational and informational purposes only